MedTrace Logo

Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

NCT07499882 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2026-03-30

No results posted yet for this study

Summary

The purpose of this observational, data collection, research is to evaluate if ziconotide, a commercially approved medication given by a FDA cleared intrathecal pump, for chronic pain is effective in the treatment of chemotherapy-induced peripheral neuropathy (CIPN) a common and often long-lasting side effect of cancer treatment.

Conditions

  • Chemotherapy Induced Peripheral Neuropathy (CIPN)

Interventions

DRUG

Ziconotide

Real world evidence trial. Patients that are on intrathecal ziconotide will be observed for two years, to determine whether or not this drug is effective for chemotherapy induced peripheral neuropathy.

Sponsors & Collaborators

  • TerSera Therapeutics LLC

    collaborator INDUSTRY

  • TeamHealth

    collaborator UNKNOWN

  • Christian Hospital Northeast Northwest

    lead OTHER

Principal Investigators

  • Christopher L Beuer, MD · BJC TeamHealth

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-02
Primary Completion
2028-05-01
Completion
2028-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07499882 on ClinicalTrials.gov